FDA Plays Nicely: Fibrocell Laviv Review Drew From Three Centers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fibrocell’s autologous cell therapy Laviv was reviewed by CBER with significant help from CDER and CDRH, providing a model of how FDA can handle high-tech products that cross traditional boundaries.